AfrEVacc
African-European HIV Vaccine Development Network
Objective
The project aims to develop a comprehensive network of institutional partners from Europe and Africa and use their existing data and expertise to build new capacity for HIV vaccine trials in Mozambique, South Africa and Tanzania.
Description
The African-European HIV Vaccine Development Network (AfrEVacc) is a multi-centre international three-year project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP). The AfrEVacc network will undertake a pilot trial of a potential vaccine candidate in clinical sites in year 2, and the sites will be ready to participate in an efficacy trial at the end of year 3.
Beyond South-North Networking, the AfrEVacc Network will greatly contribute to South-South Networking activities and to the development, acquisition and sharing of local skills and strengths.
Partners
Imperial College, United Kingdom
EuroVacc Foundation
Sanofi Pasteur SA
Centre Hospitalier Universitaire Vaudois, Division of Immunology and Allergy, Switzerland
University of KwaZulu-Natal/Africa Centre for Health and Population Studies
Medical Research Council South Africa
Wits Health Consortium (Pty) Ltd trading as the Reproductive Health & HIV Research Unit (RHRU)
Institute for Medical Microbiology and Hygiene University of Regensburg
University of Munich
Mbeya Medical Research Program
Universidade Católica de Moçambique (UCM)
University of Barcelona, Institut d’Investigacions Biomedics August Pi y Sunyer (IDIBAPS)
Funders
EDCTP
Countries
Mozambique
South Africa
Tanzania